Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SEL 110

Next Previous
Drug Profile

SEL 110

Alternative Names: ImmTOR; SEL-110; SEL-110.36; SVP Rapamycin; SVP-R

Latest Information Update: 05 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selecta Biosciences
  • Developer Cartesian Therapeutics; National Cancer Institute (USA)
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Gene therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gout
  • No development reported Immunological disorders; Inborn urea cycle disorders; Mesothelioma; Methylmalonic acidaemia

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for preclinical development in Methylmalonic-acidaemia in USA (Parenteral)
  • 28 Mar 2021 No recent reports of development identified for phase-I development in Mesothelioma(Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA (Parenteral)
  • 30 Sep 2020 Phase-III clinical trials in Gout (Treatment-experienced, Combination therapy) in USA (IV, Infusion) (NCT04596540)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top